MedTrace Logo

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2012-06-22

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis

Conditions

  • Uveitis, Posterior
  • Uveitis, Intermediate
  • Panuveitis

Interventions

DRUG

Placebo

PO BID

DRUG

LX211

0.2 mg/kg, twice a day (BID)

DRUG

LX211

0.4 mg/kg, twice a day (BID)

DRUG

LX211

0.6 mg/kg, twice a day (BID)

Sponsors & Collaborators

  • Lux Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Eddy Anglade, M.D. · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-11-30
Completion
2009-05-31

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • India
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404742 on ClinicalTrials.gov